

Gholamreza Roshandel

List of Publications by Year in descending order

Source: [//exaly.com/author-pdf/5026104/publications.pdf](https://exaly.com/author-pdf/5026104/publications.pdf)

Version: 2024-02-01

165
papers

99,221
citations

17674

60
h-index

7206

147
g-index

200
all docs

200
docs citations

200
times ranked

116781
citing authors

#	ARTICLE	IF	CITATIONS
1	Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990â€“2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet, The, 2018, 392, 1789-1858.	12.2	9,267
2	Global burden of 369 diseases and injuries in 204 countries and territories, 1990â€“2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet, The, 2020, 396, 1204-1222.	12.2	9,257
3	Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990â€“2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet, The, 2017, 390, 1211-1259.	12.2	5,921
4	Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990â€“2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet, The, 2016, 388, 1545-1602.	12.2	5,538
5	Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980â€“2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet, The, 2018, 392, 1736-1788.	12.2	5,415
6	Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980â€“2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet, The, 2016, 388, 1459-1544.	12.2	5,141
7	Global burden of 87 risk factors in 204 countries and territories, 1990â€“2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet, The, 2020, 396, 1223-1249.	12.2	4,712
8	Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990â€“2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet, The, 2016, 388, 1659-1724.	12.2	4,401
9	Global, regional, and national age-sex specific mortality for 264 causes of death, 1980â€“2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet, The, 2017, 390, 1151-1210.	12.2	3,733
10	Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks for 195 countries and territories, 1990â€“2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet, The, 2018, 392, 1923-1994.	12.2	3,512
11	Health effects of dietary risks in 195 countries, 1990â€“2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet, The, 2019, 393, 1958-1972.	12.2	3,383
12	Global, regional, and national burden of neurological disorders, 1990â€“2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurology, The, 2019, 18, 459-480.	9.9	2,958
13	Global, regional, and national disability-adjusted life-years (DALYs) for 359 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990â€“2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet, The, 2018, 392, 1859-1922.	12.2	2,298
14	Alcohol use and burden for 195 countries and territories, 1990â€“2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet, The, 2018, 392, 1015-1035.	12.2	2,233
15	Global, regional, and national burden of stroke, 1990â€“2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurology, The, 2019, 18, 439-458.	9.9	2,138
16	Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990â€“2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet, The, 2017, 390, 1345-1422.	12.2	1,969
17	Global, regional, and national disability-adjusted life-years (DALYs) for 315 diseases and injuries and healthy life expectancy (HALE), 1990â€“2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet, The, 2016, 388, 1603-1658.	12.2	1,680
18	Global, regional, and national disability-adjusted life-years (DALYs) for 333 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990â€“2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet, The, 2017, 390, 1260-1344.	12.2	1,647

#	ARTICLE	IF	CITATIONS
19	Global, regional, and national burden of neurological disorders during 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. <i>Lancet Neurology, The</i> , 2017, 16, 877-897.	9.9	1,642
20	Global, regional, and national burden of Alzheimer's disease and other dementias, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. <i>Lancet Neurology, The</i> , 2019, 18, 88-106.	9.9	1,630
21	Estimation of the global prevalence of dementia in 2019 and forecasted prevalence in 2050: an analysis for the Global Burden of Disease Study 2019. <i>Lancet Public Health, The</i> , 2022, 7, e105-e125.	9.7	1,615
22	The Burden of Primary Liver Cancer and Underlying Etiologies From 1990 to 2015 at the Global, Regional, and National Level. <i>JAMA Oncology</i> , 2017, 3, 1683.	7.4	1,536
23	Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-Years for 29 Cancer Groups, 1990 to 2016. <i>JAMA Oncology</i> , 2018, 4, 1553.	7.4	1,312
24	Prevalence and attributable health burden of chronic respiratory diseases, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. <i>Lancet Respiratory Medicine, the</i> , 2020, 8, 585-596.	10.3	1,196
25	Global, regional, and national burden of traumatic brain injury and spinal cord injury, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. <i>Lancet Neurology, The</i> , 2019, 18, 56-87.	9.9	1,194
26	Global age-sex-specific fertility, mortality, healthy life expectancy (HALE), and population estimates in 204 countries and territories, 1950–2019: a comprehensive demographic analysis for the Global Burden of Disease Study 2019. <i>Lancet, The</i> , 2020, 396, 1160-1203.	12.2	1,056
27	The global, regional, and national burden of cirrhosis by cause in 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. <i>The Lancet Gastroenterology and Hepatology</i> , 2020, 5, 245-266.	8.0	951
28	Global, regional, and national age-sex-specific mortality and life expectancy, 1950–2017: a systematic analysis for the Global Burden of Disease Study 2017. <i>Lancet, The</i> , 2018, 392, 1684-1735.	12.2	813
29	Global, regional, and national levels of maternal mortality, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. <i>Lancet, The</i> , 2016, 388, 1775-1812.	12.2	782
30	Measuring performance on the Healthcare Access and Quality Index for 195 countries and territories and selected subnational locations: a systematic analysis from the Global Burden of Disease Study 2016. <i>Lancet, The</i> , 2018, 391, 2236-2271.	12.2	678
31	Global, regional, national, and selected subnational levels of stillbirths, neonatal, infant, and under-5 mortality, 1980–2015: a systematic analysis for the Global Burden of Disease Study 2015. <i>Lancet, The</i> , 2016, 388, 1725-1774.	12.2	604
32	Global, regional, and national under-5 mortality, adult mortality, age-specific mortality, and life expectancy, 1970–2016: a systematic analysis for the Global Burden of Disease Study 2016. <i>Lancet, The</i> , 2017, 390, 1084-1150.	12.2	594
33	Healthcare Access and Quality Index based on mortality from causes amenable to personal health care in 195 countries and territories, 1990–2015: a novel analysis from the Global Burden of Disease Study 2015. <i>Lancet, The</i> , 2017, 390, 231-266.	12.2	511
34	Estimates of global, regional, and national incidence, prevalence, and mortality of HIV, 1980–2015: the Global Burden of Disease Study 2015. <i>Lancet HIV, the</i> , 2016, 3, e361-e387.	4.5	469
35	Global Burden of Multiple Myeloma. <i>JAMA Oncology</i> , 2018, 4, 1221.	7.4	441
36	Measuring the health-related Sustainable Development Goals in 188 countries: a baseline analysis from the Global Burden of Disease Study 2015. <i>Lancet, The</i> , 2016, 388, 1813-1850.	12.2	433

#	ARTICLE	IF	CITATIONS
37	The global, regional, and national burden of stomach cancer in 195 countries, 1990–2017: a systematic analysis for the Global Burden of Disease study 2017. <i>The Lancet Gastroenterology and Hepatology</i> , 2020, 5, 42-54.	8.0	421
38	The global, regional, and national burden of pancreatic cancer and its attributable risk factors in 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. <i>The Lancet Gastroenterology and Hepatology</i> , 2019, 4, 934-947.	8.0	414
39	Five insights from the Global Burden of Disease Study 2019. <i>Lancet, The</i> , 2020, 396, 1135-1159.	12.2	390
40	Measuring universal health coverage based on an index of effective coverage of health services in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. <i>Lancet, The</i> , 2020, 396, 1250-1284.	12.2	365
41	Measuring progress from 1990 to 2017 and projecting attainment to 2030 of the health-related Sustainable Development Goals for 195 countries and territories: a systematic analysis for the Global Burden of Disease Study 2017. <i>Lancet, The</i> , 2018, 392, 2091-2138.	12.2	357
42	Population and fertility by age and sex for 195 countries and territories, 1950–2017: a systematic analysis for the Global Burden of Disease Study 2017. <i>Lancet, The</i> , 2018, 392, 1995-2051.	12.2	313
43	Measuring progress and projecting attainment on the basis of past trends of the health-related Sustainable Development Goals in 188 countries: an analysis from the Global Burden of Disease Study 2016. <i>Lancet, The</i> , 2017, 390, 1423-1459.	12.2	289
44	The global, regional, and national burden of colorectal cancer and its attributable risk factors in 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. <i>The Lancet Gastroenterology and Hepatology</i> , 2019, 4, 913-933.	8.0	286
45	The global, regional, and national burden of oesophageal cancer and its attributable risk factors in 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. <i>The Lancet Gastroenterology and Hepatology</i> , 2020, 5, 582-597.	8.0	265
46	Global, regional, and national burden of meningitis, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. <i>Lancet Neurology, The</i> , 2018, 17, 1061-1082.	9.9	236
47	The global burden of childhood and adolescent cancer in 2017: an analysis of the Global Burden of Disease Study 2017. <i>Lancet Oncology, The</i> , 2019, 20, 1211-1225.	10.2	223
48	Effectiveness of polypill for primary and secondary prevention of cardiovascular diseases (PolyIran): a pragmatic, cluster-randomised trial. <i>Lancet, The</i> , 2019, 394, 672-683.	12.2	213
49	Mapping 123 million neonatal, infant and child deaths between 2000 and 2017. <i>Nature</i> , 2019, 574, 353-358.	36.3	175
50	Health in times of uncertainty in the eastern Mediterranean region, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. <i>The Lancet Global Health</i> , 2016, 4, e704-e713.	6.0	154
51	Individual and Combined Effects of Environmental Risk Factors for Esophageal Cancer Based on Results From the Golestan Cohort Study. <i>Gastroenterology</i> , 2019, 156, 1416-1427.	1.4	129
52	Cancer incidence in Iran in 2014: Results of the Iranian National Population-based Cancer Registry. <i>Cancer Epidemiology</i> , 2019, 61, 50-58.	2.1	116
53	The Burden of Mental Disorders in the Eastern Mediterranean Region, 1990-2013. <i>PLoS ONE</i> , 2017, 12, e0169575.	2.4	110
54	Global, regional, and national burden of respiratory tract cancers and associated risk factors from 1990 to 2019: a systematic analysis for the Global Burden of Disease Study 2019. <i>Lancet Respiratory Medicine, the</i> , 2021, 9, 1030-1049.	10.3	106

#	ARTICLE	IF	CITATIONS
55	Fumonisin B1 Contamination of Cereals and Risk of Esophageal Cancer in a High Risk Area in Northeastern Iran. <i>Asian Pacific Journal of Cancer Prevention</i> , 2012, 13, 2625-2628.	1.2	101
56	Fixed-dose combination therapies with and without aspirin for primary prevention of cardiovascular disease: an individual participant data meta-analysis. <i>Lancet, The</i> , 2021, 398, 1133-1146.	12.2	100
57	The global, regional, and national burden of gastro-oesophageal reflux disease in 195 countries and territories, 1990â€“2017: a systematic analysis for the Global Burden of Disease Study 2017. <i>The Lancet Gastroenterology and Hepatology</i> , 2020, 5, 561-581.	8.0	83
58	Association between heavy metals and colon cancer: an ecological study based on geographical information systems in North-Eastern Iran. <i>BMC Cancer</i> , 2021, 21, 414.	2.6	76
59	Cancer in Iran 2008 to 2025: Recent incidence trends and short-term predictions of the future burden. <i>International Journal of Cancer</i> , 2021, 149, 594-605.	5.4	72
60	Opium use and subsequent incidence of cancer: results from the Golestan Cohort Study. <i>The Lancet Global Health</i> , 2020, 8, e649-e660.	6.0	64
61	Urinary TERT promoter mutations are detectable up to 10 years prior to clinical diagnosis of bladder cancer: Evidence from the Golestan Cohort Study. <i>EBioMedicine</i> , 2020, 53, 102643.	6.1	54
62	Burden of injury along the development spectrum: associations between the Socio-demographic Index and disability-adjusted life year estimates from the Global Burden of Disease Study 2017. <i>Injury Prevention</i> , 2020, 26, i12-i26.	2.2	50
63	A Diversity of Cancer Incidence and Mortality in West Asian Populations. <i>Annals of Global Health</i> , 2018, 80, 346.	2.1	46
64	Esophageal Cancer in Golestan Province, Iran: A Review of Genetic Susceptibility and Environmental Risk Factors. <i>Middle East Journal of Digestive Diseases</i> , 2016, 8, 249-266.	0.4	45
65	Epidemiological Pattern of Breast Cancer in Iranian Women: Is there an Ethnic Disparity?. <i>Asian Pacific Journal of Cancer Prevention</i> , 2012, 13, 4517-4520.	1.2	44
66	Aflatoxin contamination of wheat flour and the risk of esophageal cancer in a high risk area in Iran. <i>Cancer Epidemiology</i> , 2013, 37, 290-293.	2.1	35
67	Building cancer registries in a lower resource setting: The 10-year experience of Golestan, Northern Iran. <i>Cancer Epidemiology</i> , 2018, 52, 128-133.	2.1	35
68	Pictogram use was validated for estimating individual's body mass index. <i>Journal of Clinical Epidemiology</i> , 2010, 63, 655-659.	5.1	34
69	Worldwide trends in population-based survival for children, adolescents, and young adults diagnosed with leukaemia, by subtype, during 2000â€“14 (CONCORD-3): analysis of individual data from 258 cancer registries in 61 countries. <i>The Lancet Child and Adolescent Health</i> , 2022, 6, 409-431.	5.6	31
70	Oral health and mortality in the Golestan Cohort Study. <i>International Journal of Epidemiology</i> , 2017, 46, 2028-2035.	2.1	30
71	Marked increase in breast cancer incidence in young women: A 10-year study from Northern Iran, 2004â€“2013. <i>Cancer Epidemiology</i> , 2019, 62, 101573.	2.1	29
72	Epidemiology of Leukemia and Multiple Myeloma in Golestan, Iran. <i>Asian Pacific Journal of Cancer Prevention</i> , 2013, 14, 2333-2336.	1.2	29

#	ARTICLE	IF	CITATIONS
73	Soils selenium level and esophageal cancer: An ecological study in a high risk area for esophageal cancer. <i>Journal of Trace Elements in Medicine and Biology</i> , 2010, 24, 174-177.	3.2	28
74	Burden of Diarrhea in the Eastern Mediterranean Region, 1990â€“2013: Findings from the Global Burden of Disease Study 2013. <i>American Journal of Tropical Medicine and Hygiene</i> , 2016, 95, 1319-1329.	1.4	28
75	Opiate and Tobacco Use and Exposure to Carcinogens and Toxicants in the Golestan Cohort Study. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2020, 29, 650-658.	2.0	25
76	Genome expression analysis by suppression subtractive hybridization identified overexpression of Humanin, a target gene in gastric cancer chemoresistance. <i>DARU, Journal of Pharmaceutical Sciences</i> , 2014, 22, 14.	2.1	24
77	Serum Leptin Levels and Irritable Bowel Syndrome. <i>Journal of Clinical Gastroenterology</i> , 2009, 43, 826-830.	2.4	23
78	Household Fuel Use and the Risk of Gastrointestinal Cancers: The Golestan Cohort Study. <i>Environmental Health Perspectives</i> , 2020, 128, 67002.	8.1	23
79	Effect of Lactocare® Synbiotic on Disease Severity in Ulcerative Colitis: A Randomized Placebo-Controlled Double-Blind Clinical Trial. <i>Middle East Journal of Digestive Diseases</i> , 2020, 12, 27-33.	0.4	22
80	Predictors of Colorectal Cancer Survival in Golestan, Iran: A Population-based Study. <i>Epidemiology and Health</i> , 2013, 35, e2013004.	1.9	21
81	Epidemiology of <i>Helicobacter pylori</i> infection among Iranian children. <i>Arab Journal of Gastroenterology</i> , 2013, 14, 169-172.	0.9	20
82	Temporal and geographical variations in colorectal cancer incidence in Northern Iran 2004â€“2013. <i>Cancer Epidemiology</i> , 2019, 59, 143-147.	2.1	20
83	Epidemiology of Female Reproductive Cancers in Iran: Results of the Cholestan Population-Based Cancer Registry. <i>Asian Pacific Journal of Cancer Prevention</i> , 2014, 15, 8779-8782.	1.2	20
84	Untargeted Metabolomics: Biochemical Perturbations in Golestan Cohort Study Opium Users Inform Intervention Strategies. <i>Frontiers in Nutrition</i> , 2020, 7, 584585.	3.8	19
85	Letter to the editor: efficacy of different methods of combination regimen administrations including dexamethasone, intravenous immunoglobulin, and interferon-beta to treat critically ill COVID-19 patients: a structured summary of a study protocol for a randomized controlled trial. <i>Trials</i> , 2020, 21, 549.	1.7	19
86	Long-term opiate use and risk of cardiovascular mortality: results from the Golestan Cohort Study. <i>European Journal of Preventive Cardiology</i> , 2021, 28, 98-106.	1.9	18
87	Cost-effectiveness of fixed-dose combination pill (Polypill) in primary and secondary prevention of cardiovascular disease: A systematic literature review. <i>PLoS ONE</i> , 2022, 17, e0271908.	2.4	18
88	Association Between <i>Helicobacter pylori</i> Colonization and Inflammatory Bowel Disease. <i>Journal of Clinical Gastroenterology</i> , 2021, 55, 380-392.	2.4	17
89	Overexpression of FOXO3, MYD88, and GAPDH Identified by Suppression Subtractive Hybridization in Esophageal Cancer Is Associated with Autophagy. <i>Gastroenterology Research and Practice</i> , 2014, 2014, 1-8.	1.6	16
90	Recent cancer incidence trends and short-term predictions in Golestan, Iran 2004â€“2025. <i>Cancer Epidemiology</i> , 2020, 67, 101728.	2.1	15

#	ARTICLE	IF	CITATIONS
91	Fixed-Dose Combination Therapy for the Prevention of Cardiovascular Diseases in CKD. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2023, 18, 1408-1415.	4.6	15
92	Metabolomics reveals biomarkers of opioid use disorder. <i>Translational Psychiatry</i> , 2021, 11, 103.	5.0	14
93	Prevalence of Hepatitis D Virus Infection in HBsAg Positive Subjects in Iran. <i>Pakistan Journal of Biological Sciences</i> , 2007, 10, 1751-1754.	0.5	14
94	Oral Health and Risk of Upper Gastrointestinal Cancers in a Large Prospective Study from a High-risk Region: Golestan Cohort Study. <i>Cancer Prevention Research</i> , 2021, 14, 709-718.	1.6	13
95	Meat consumption and risk of esophageal and gastric cancer in the Golestan Cohort Study, Iran. <i>International Journal of Cancer</i> , 2022, 151, 1005-1012.	5.4	13
96	Modifiable Risk of Breast Cancer in Northeast Iran: Hope for the Future. A Case-Control Study. <i>Breast Care</i> , 2011, 6, 453-456.	1.5	12
97	Effects of omeprazole consumption on serum levels of trace elements. <i>Journal of Trace Elements in Medicine and Biology</i> , 2012, 26, 234-237.	3.2	12
98	A simple risk-based strategy for hepatitis C virus screening among incarcerated people in a low- to middle-income setting. <i>Harm Reduction Journal</i> , 2020, 17, 56.	3.3	12
99	Development of a tool for comprehensive evaluation of population-based cancer registries. <i>International Journal of Medical Informatics</i> , 2018, 117, 26-32.	3.5	11
100	Gastric Cancer in Iran: An Overview of Risk Factors and Preventive Measures. <i>Archives of Iranian Medicine</i> , 2021, 24, 556-567.	0.7	11
101	Goiter Frequency Is More Strongly Associated with Gastric Adenocarcinoma than Urine Iodine Level. <i>Journal of Gastric Cancer</i> , 2013, 13, 106.	2.5	10
102	Comparison of the Serum Levels of Trace Elements in Areas with High or Low Rate of Esophageal Cancer. <i>Middle East Journal of Digestive Diseases</i> , 2017, 9, 81-85.	0.4	10
103	Estimating Completeness of Cancer Registration in Iran with Capture-Recapture Methods. <i>Asian Pacific Journal of Cancer Prevention</i> , 2016, 17, 93-99.	1.2	10
104	Ethical issues in cluster randomized trials conducted in low- and middle-income countries: an analysis of two case studies. <i>Trials</i> , 2020, 21, 314.	1.7	9
105	Joint effect of diabetes and opiate use on all-cause and cause-specific mortality: the Golestan cohort study. <i>International Journal of Epidemiology</i> , 2021, 50, 314-324.	2.1	9
106	The possible impact of sortilin in reducing HBsAg expression in chronic hepatitis B. <i>Journal of Medical Virology</i> , 2016, 88, 647-652.	5.1	8
107	National surveillance of cancer survival in Iran (<scp>IRANCANSURV</scp>): Analysis of data of 15 cancer sites from nine population-based cancer registries. <i>International Journal of Cancer</i> , 2022, 151, 2128-2135.	5.4	8
108	Trends in the Incidence of Stomach Cancer in Golestan Province, a High-risk Area in Northern Iran, 2004-2016. <i>Archives of Iranian Medicine</i> , 2020, 23, 362-368.	0.7	7

#	ARTICLE	IF	CITATIONS
109	Diagnostic Values of Serum Levels of Pepsinogens and Gastrin-17 for Screening Gastritis and Gastric Cancer in a High Risk Area in Northern Iran. <i>Asian Pacific Journal of Cancer Prevention</i> , 2014, 15, 7433-7436.	1.2	7
110	Lead poisoning among asymptomatic individuals with a long-term history of opiate use in Golestan Cohort Study. <i>International Journal of Drug Policy</i> , 2022, 104, 103695.	3.5	7
111	Effect of Lead Intoxication and D-Penicillamine Treatment on Hematological Indices in Rats. <i>International Journal of Morphology</i> , 2007, 25, .	0.3	6
112	Depressive mood and disease activity in inflammatory bowel disease. <i>Arab Journal of Gastroenterology</i> , 2012, 13, 136-138.	0.9	6
113	TP53 Targeted Deep Sequencing of Cell-Free DNA in Esophageal Squamous Cell Carcinoma Using Low-Quality Serum: Concordance with Tumor Mutation. <i>International Journal of Molecular Sciences</i> , 2021, 22, 5627.	4.2	6
114	Should we look for Celiac Disease in Irritable Bowel Syndrome?. <i>Oman Medical Journal</i> , 2011, 26, 59-60.	0.9	5
115	Assessing the Correlation of Fecal Calprotectin and the Clinical Disease Activity Index in Patients With Ulcerative Colitis. <i>Gastroenterology Nursing</i> , 2018, 41, 201-205.	0.5	5
116	Strontium and antimony serum levels in healthy individuals living in high- and low-risk areas of esophageal cancer. <i>Journal of Clinical Laboratory Analysis</i> , 2020, 34, e23269.	2.1	5
117	Associations between Biomarkers of Exposure and Lung Cancer Risk among Exclusive Cigarette Smokers in the Golestan Cohort Study. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 7349.	2.8	5
118	Bowel Preparation for a Better Colonoscopy Using Polyethylene Glycol or C-lax: A Double Blind Randomized Clinical Trial. <i>Middle East Journal of Digestive Diseases</i> , 2017, 9, 212-217.	0.4	5
119	Self-Monitoring by Traffic Light Color Coding Versus Usual Care on Outcomes of Patients With Heart Failure Reduced Ejection Fraction: Protocol for a Randomized Controlled Trial. <i>JMIR Research Protocols</i> , 2018, 7, e184.	1.1	5
120	10-Year Trends in Dietary Intakes in the High- and Low-Risk Areas for Esophageal Cancer: A Population-Based Ecological Study in Northern Iran. <i>Middle East Journal of Digestive Diseases</i> , 2020, 12, 89-98.	0.4	5
121	Hepatitis B virus genotypes in Iran. <i>Indian Journal of Medical Sciences</i> , 2008, 62, 204.	0.1	5
122	National Cancer Mortality-to-Incidence Ratio (MIR) in Iran (2005 - 2014). <i>International Journal of Cancer Management</i> , 2019, 12, .	0.4	5
123	Temporal and Geographical Trends of Incidence of Thyroid Cancer in Golestan, Iran, 2004-2013. <i>Archives of Iranian Medicine</i> , 2021, 24, 1-6.	0.7	4
124	Geo-epidemiological reporting and spatial clustering of the 10 most prevalent cancers in Iran. <i>Geospatial Health</i> , 2021, 16, .	0.9	4
125	Clinical features, risk factors and a prediction model for in-hospital mortality among diabetic patients infected with COVID-19: data from a referral centre in Iran. <i>Public Health</i> , 2022, 202, 84-92.	3.0	4
126	Population-based cancer survival in the Golestan province in the northeastern part of Iran 2007-2012. <i>Cancer Epidemiology</i> , 2022, 77, 102089.	2.1	4

#	ARTICLE	IF	CITATIONS
127	Urinary nitrate and sodium in a high-risk area for upper gastrointestinal cancers: Golestan Cohort Study†. <i>Environmental Research</i> , 2022, 214, 113906.	7.7	4
128	Population attributable proportion and number of cancer cases attributed to potentially modifiable risk factors in Iran in 2020. <i>International Journal of Cancer</i> , 2023, 153, 1758-1765.	5.4	4
129	Colorectal Cancer: Epidemiology, Risk Factors, and Prevention. <i>Cancers</i> , 2024, 16, 1530.	3.9	4
130	Factors Associated with Outcome in Patients with Acute Upper Gastrointestinal Bleeding in a Tertiary Referral Center in Northern Iran. <i>Middle East Journal of Digestive Diseases</i> , 2016, 8, 201-205.	0.4	3
131	Temporal Variations of Dietary Habits in a High-Risk Area for Upper Gastrointestinal Cancers: a Population-Based Study from Northern Iran. <i>Asian Pacific Journal of Cancer Prevention</i> , 2015, 16, 2537-2542.	1.2	3
132	Sex and smoking differences in the association between gastroesophageal reflux and risk of esophageal squamous cell carcinoma in a high-incidence area: Golestan Cohort Study. <i>International Journal of Cancer</i> , 2023, 152, 1137-1149.	5.4	3
133	Esophageal and gastric cancer incidence trends in Golestan, Iran: An age-period-cohort analysis 2004 to 2018. <i>International Journal of Cancer</i> , 2023, 153, 73-82.	5.4	3
134	Increasing trends of lung cancer in Golestan province, Northern Iran (2004-2016). <i>Cancer Epidemiology</i> , 2020, 65, 101687.	2.1	2
135	Use of multidimensional item response theory methods for dementia prevalence prediction: an example using the Health and Retirement Survey and the Aging, Demographics, and Memory Study. <i>BMC Medical Informatics and Decision Making</i> , 2021, 21, 241.	3.1	2
136	Dynamics of the COVID-19 Clinical Findings and the Serologic Response. <i>Frontiers in Microbiology</i> , 2021, 12, 743048.	3.6	2
137	Trends in the Incidence Rates of Breast and Gynecological Cancers in Asia from 1998-2012: An Ecological Study. <i>Archives of Iranian Medicine</i> , 2022, 25, 112-117.	0.7	2
138	Colorectal cancer incidence trends in Golestan, Iran: An age-period-cohort analysis 2004-2018. <i>Cancer Epidemiology</i> , 2023, 86, 102415.	2.1	2
139	Effect of gilbert's syndrome associated polymorphic alleles (rs8175347 and rs4148323) of UDP-glucuronyl transferase on serum bilirubin level. <i>Meta Gene</i> , 2020, 26, 100788.	0.6	1
140	An intervention to increase hepatitis C virus diagnosis and treatment uptake among people in custody in Iran. <i>International Journal of Drug Policy</i> , 2021, 95, 103269.	3.5	1
141	Morphometric Changes of Rat Testis after Subchronic Oral Lead Intoxication and D-Penicillamine Treatment. <i>Pakistan Journal of Biological Sciences</i> , 2006, 9, 1310-1314.	0.5	1
142	Higher Serum Levels of Type I Interferon Receptor in Adults with Chronic Hepatitis B Leading to Hepatitis B Surface Antigen Clearance. <i>Jundishapur Journal of Microbiology</i> , 2017, 10, .	0.5	1
143	All-Cause and Cause-Specific Mortality in Middle-Aged Individuals with Positive HBsAg: Findings from a Prospective Cohort Study. <i>Archives of Iranian Medicine</i> , 2022, 25, 139-147.	0.7	1
144	Risk factors of in-hospital mortality for isolated on-pump coronary artery bypass graft surgery in the northeast of Iran from 2007 to 2016. <i>Irish Journal of Medical Science</i> , 0, , .	1.7	1

#	ARTICLE	IF	CITATIONS
145	Type 2 diabetes mellitus and In-hospital Major Adverse Cardiac and Cerebrovascular Events (MACCEs) and postoperative complications among patients undergoing on-pump isolated coronary artery bypass surgery in Northeastern Iran. <i>BMC Cardiovascular Disorders</i> , 2023, 23, .	1.7	1
146	Regional disparities in cancer survival in Iran: Insight from a National Surveillance of Cancer Survival in Iran (IRANCANSURV). <i>Cancer Epidemiology</i> , 2023, 85, 102378.	2.1	1
147	Uterine and Cervical Cancer in Iran: An epidemiologic analysis of the Iranian National Population-Based Cancer Registry. <i>Archives of Iranian Medicine</i> , 2023, 26, 1-7.	0.7	1
148	Exposure to polycyclic aromatic hydrocarbons, volatile organic compounds, and tobacco-specific nitrosamines and incidence of esophageal cancer. <i>Journal of the National Cancer Institute</i> , 2024, 116, 379-388.	6.6	1
149	Breast cancer incidence trends in Golestan, Iran: An age-period-cohort analysis by ethnic region, 2004-2018. <i>Cancer Epidemiology</i> , 2024, 89, 102525.	2.1	1
150	Polypill for prevention of cardiovascular diseases – Authors' reply. <i>Lancet</i> , The, 2020, 395, 414-415.	12.2	0
151	Building a Cancer Biobank in a Low-Resource Setting in Northern Iran: the Golestan Cancer Biobank. <i>Archives of Iranian Medicine</i> , 2021, 24, 526-533.	0.7	0
152	Assessment of Bone Mineral Density in Patients Undergoing Hemodialysis; An Iranian Population-Based Study. <i>Archives of Iranian Medicine</i> , 2021, 24, 599-606.	0.7	0
153	HBV/HCV Co-infection in Iran: A Seroepidemiological Based Study. <i>Pakistan Journal of Biological Sciences</i> , 2006, 9, 2538-2540.	0.5	0
154	Irritable Bowel Syndrome in Iranian Young Adults: A Survey among Medical Students. <i>Journal of Medical Sciences (Faisalabad, Pakistan)</i> , 2006, 6, 974-978.	0.0	0
155	Gastrointestinal Complaints and Treatment of <i>Helicobacter pylori</i> in Children: A Narrative Review. <i>Journal of Pediatrics Review</i> , 2016, In Press, .	0.3	0
156	Vaccine Therapy in Chronic Hepatitis B Carriers: A Randomised Double-Blind Controlled Trial. <i>Journal of Clinical and Diagnostic Research JCDR</i> , 0, , .	0.8	0
157	Analysis of Competing Risks of Causes of Death in Cancer Patients from Golestan, Iran over Twelve Years (2004-2016). <i>Asian Pacific Journal of Cancer Prevention</i> , 2021, 22, 3137-3142.	1.2	0
158	Primary Liver Cancer in Golestan Province, Northeastern Iran: 13-Year Experience of Golestan Population-Based Cancer Registry (GPCR). <i>Archives of Iranian Medicine</i> , 2021, 24, 727-732.	0.7	0
159	Detection Rate of Colorectal Polyps in Symptomatic Candidates of Colonoscopy: When Should We Do a Total Colonoscopy?. <i>Middle East Journal of Digestive Diseases</i> , 2021, 13, 314-320.	0.4	0
160	Incidence, Time Trends and Geographical Distribution of Leukemia and Multiple Myeloma in Golestan Province, Northern Iran, 2004-2017. <i>Archives of Iranian Medicine</i> , 2022, 25, 360-365.	0.7	0
161	Temporal Pattern and Age-Period-Cohort Analysis of Breast Cancer Incidence in Iranian Women (2009-2017). <i>Archives of Iranian Medicine</i> , 2023, 26, 285-289.	0.7	0
162	Ethnic Disparities in Major Adverse Cardiac and Cerebrovascular Events (MACCEs) and Postoperative Outcomes Following Coronary Artery Bypass in Northeastern Iran (2007-2016). <i>Archives of Iranian Medicine</i> , 2023, 26, 554-560.	0.7	0

#	ARTICLE	IF	CITATIONS
163	Incidence Rates and Time Trends of Skin Cancer in Golestan Province, Northeastern Iran, 2005-2018. Archives of Iranian Medicine, 0, , .	0.7	0
164	Cost effectiveness analysis of a fixed dose combination pill for primary prevention of cardiovascular disease from an individual participant data meta-analysis. EClinicalMedicine, 2024, 73, 102651.	7.2	0
165	Oneâ€carbon metabolism biomarkers and upper gastrointestinal cancer in the Golestan Cohort Study. International Journal of Cancer, 0, , .	5.4	0